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Background, aims and methodology
Preventing new HIV infections is critical. However, less than 
one in five people has access to proven prevention methods,1 
and ‘for every person placed on antiretroviral treatment in 
2006, another six people became newly infected with HIV’.2 
Efforts to utilise existing prevention strategies better, and 
to identify new ones, are therefore imperative.3 Apart from 
male circumcision, results of several prevention trials have 
been disappointing, including the use of acyclovir to reduce 
HIV transmission by suppressing herpes simplex virus type 
2 (HSV2). Although not statistically significant, the PRO 2000 
microbicide gel results are promising and more results, such as 
pre-exposure prophylaxis (PrEP), are expected in the next few 
years. 
As South Africa is the epicentre of the HIV epidemic, several 
clinical trials have been conducted or are ongoing, including 
HIV vaccines, microbicides, PrEP, herpes suppression, cervical 
barriers, male circumcision and behavioural interventions.4 
Several preventive HIV vaccine trials (HVTs) have been 
conducted in South Africa since 2003 (5 phase I trials, 2 phase 
II trials, and 1 phase IIb trial). Three of these are ongoing, 
namely HVTN 204, a phase II trial assessing the safety and 
immunogenicity of a multiclade HIV-1 DNA vaccine boosted 
by a multiclade HIV-1 Ad5 vaccine in HIV-uninfected adults, in 
which 240 of the 480  participants are South Africans who have 
received all their vaccinations and are being followed up for 
long-term safety and immunogenicity; the SAAVI 102/HVTN 
073 trial, investigating the multigene sub-type C SAAVI DNA-
C2 and MVA-C vaccine, a phase I trial currently enrolling 
participants, of whom 36 out of the 48 will be enrolled in 
South Africa; and the HVTN 503 phase IIB trial, in which 801 
participants are being followed up after further enrolments and 
vaccinations were halted. 
We outline the complexities facing researchers with 
regard to their prevention responsibilities in HVTs and 
make recommendations for future work. A literature search 
of electronic databases and key websites was conducted 
for publications relating to the standard of prevention. A 
conceptual analysis of this literature and key ethical guidelines 
pertaining to HVTs was undertaken. 
Responsibility to provide proven/
established effective methods 
Current international ethical guidelines2 assert that ‘researchers, 
research staff and trial sponsors should ensure that … access 
to all state of the art HIV risk reduction methods are provided 
to participants’ (Guidance Point (GP) 13, p. 45), they should 
‘receive all established effective HIV risk reduction measures’ (GP 
15, p. 51) and participants are ‘entitled’ to proven prevention 
methods. South African guidance articulates that participants 
should receive access to preventive methods,5 later described 
as ‘optimal’ (p. 28) (our emphasis throughout the above 
paragraph). 
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Researchers should protect the welfare of research 
participants through providing methods to reduce their risk 
of acquiring HIV. This is especially important given that late-
phase HIV vaccine trials enrol HIV-uninfected trial volunteers 
from high-risk populations. 
Current ethical guidelines may be difficult for stakeholders to 
implement, and we know very little about what prevention 
services researchers are currently providing to participants or 
their successes, best practices and challenges. We recommend 
that current normative guidance be systematically reviewed 
and actual practice at vaccine sites be documented.
Adding new tools to the current package of prevention 
services will involve complex decision making with few 
set standards, and regulatory and scientific challenges. We 
recommend that stakeholders (including regulators) convene 
to consider standards of evidence for new tools, and that 
decision-making processes be explicitly documented and 
researched. A further critical ethical task is exploring the 
threshold at which adding new tools will compromise the 
validity of trial results. 
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UNAIDS-WHO2 outlines that all trial participants should 
receive access to risk reduction counselling on safer sex, 
education concerning general health, the benefits of post-
exposure prophylaxis (PEP) and strategies to reduce domestic 
violence; male and female condoms; sexually transmitted 
infection (STI) treatment; sterile injecting equipment 
and medical substitution therapies such as methadone 
maintenance; PEP; and reproductive health care services 
including access to family planning, appropriate contraception, 
pregnancy and childbirth services. The South African guidance 
concurs on access to counselling, condoms, STI treatment and 
counselling on the benefits of PEP (cf. MRC5). Some of the tools 
available to make up the package of prevention are reviewed 
below. 
Currently available tools for HIV prevention 
There is increasing evidence of the effectiveness of male 
condoms in preventing HIV infection.6 From longitudinal 
cohort studies with sero-discordant couples the effectiveness 
of male condoms has been estimated at approximately 80%, 
but their precise degree of protection is unknown owing to 
complexities that make randomised controlled trials (RCTs) of 
efficacy unethical.7 The female condom is currently the only 
available female-initiated prevention method and has also been 
estimated to be highly effective in preventing HIV infection.6 
Education and risk-reduction counselling is a key 
component of HVTs.8 However, while some studies suggest 
that behavioural risk-reduction interventions are effective 
in reducing risk behaviours,8 none demonstrate significant 
reduction in HIV infection rates.3 Data from community 
randomised trials on the impact of STI treatment on HIV 
infection are mixed. An initial study reported a significant 
decrease in HIV when STIs were treated through syndromic 
management, but subsequent trials found no effect on HIV.6 
For ethical and logistic reasons, RCTs of non-occupational 
PEP are unlikely to be conducted.9 However, data from animal 
transmission models and observational studies suggest that 
non-occupational PEP ‘might sometimes reduce the risk for 
HIV infection after nonoccupational exposures’9 (p. 2). 
Sharing contaminated needles is a major driver of HIV 
infection among injection drug users (IDUs). RCTs and case 
studies have shown that drug substitution therapy is effective 
in preventing the transmission of HIV among IDUs.10 While 
RCTs of needle exchange programmes may not be feasible, 
evidence suggests that access to sterile injecting equipment 
is effective in preventing HIV transmission.10 Three RCTs 
conducted in Africa indicated that circumcision at least 
halves a man’s risk of contracting HIV through heterosexual 
sex. The male circumcision trial conducted in Orange Farm, 
South Africa, was stopped early after an interim review of 
data revealed that circumcision decreased the chances of 
acquiring HIV by 60%.11 Studies in Kenya and Uganda to 
assess the applicability of the South African findings in other 
contexts were also halted after interim data suggested a ‘highly 
significant reduced risk of HIV seroconversion among the men 
randomly assigned to circumcision’11 (p. 568).
Complexities of providing proven/established 
effective tools
It is not clear when a prevention method is considered ‘proven’ 
or ‘established effective’. While RCTs are considered the 
gold standard for establishing the efficacy of interventions, 
most of the currently accepted effective HIV prevention tools 
(e.g. condoms) were not subject to such rigorous testing.12 
An ‘established effective’ intervention has been defined as 
one which is accepted by the international medical profession as 
being as successful as any intervention in addressing an issue; 
however, consensus among experts is difficult to achieve and 
evaluate.13 
Additionally, there are omissions from, and contradictions 
in, key ethical guidelines. Examples include that male 
circumcision receives no discussion as a recommended risk-
reduction method under the guidance point on standard of 
prevention in the UNAIDS-WHO2 guidelines. These same 
guidelines recommend that risk-reduction counselling possibly 
be provided by an independent agency owing to concerns 
around conflict of interest;2 however, other prevention services 
apparently do not raise such concerns. Also, the UNAIDS-
AVAC14 guidelines set a very high procedural standard, 
including that  researchers should consult with stakeholders, 
document the consultations, map service providers that will 
support sites, build capacity to do so, and monitor uptake of 
prevention services. Trials should also not be conducted in 
circumstances when ‘agreements have not been reached among 
all research stakeholders on [the] standard of prevention’2 (p. 
13). 
Furthermore, there has been little empirical investigation 
of the prevention services provided to participants in HVTs. 
More attention has been paid to microbicide and diaphragm 
studies where three South African sites have been researched.15 
It was found that participants do receive intensive quality 
counselling, unlimited free male condoms and quality STI 
services; however, female condoms were not actively promoted 
by site staff.15 There has also been little comparison of how 
ethical guidelines correspond with actual practice at HVT sites 
or with the actual dilemmas experienced by researchers.  
Recommendations for addressing complexities with 
providing currently available tools
1.    Guidelines must be formally evaluated to highlight 
where guidance is least clear, to bring the most relevant 
guidance to the foreground, and to clarify researchers’ 
responsibilities. 
2.    Prevention services offered to HVT participants, as well as 
decision-making practices, should be assessed.
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3.    It should be assessed whether practices correspond with 
ethical guidelines, and whether ethical guidelines provide 
direction on researchers’ actual dilemmas.  
Obligation to add new methods 
Current international ethical guidance asserts that researchers, 
research staff and sponsors provide new methods to trial 
participants when they are ‘scientifically validated or approved 
by the relevant authorities’.2 Researchers must spell out how 
‘enhancement’ of the package will be negotiated, considering 
factors such as feasibility, expected impact, and ability to 
isolate the efficacy of the new modality being tested. South 
African guidance states that new methods are added as they are 
‘discovered and validated’.5
What new methods could become part of the 
prevention package?
Pre-exposure prophylaxis (PrEP). Researchers are trying to 
determine whether antiretroviral drugs (ARVs) used to treat 
HIV/AIDS could be used as a prevention strategy. Currently 
four clinical trials are testing the safety and efficacy of PrEP 
with ARVs for HIV prevention. Tenofovir trials are being 
carried out among HIV-uninfected men who have sex with 
men (MSM) and IDUs. Results are expected in 2009 and 2010, 
respectively.4 The PrEP candidate Truvada is being clinically 
tested in large-scale multicentre efficacy studies with MSM 
and with heterosexual men and women. Results are expected 
in 2010 and 2011, respectively.4 An efficacy study is also 
comparing the effectiveness of tenofovir with Truvada in 
serodiscordant heterosexual couples. Results are expected 
in 2012.4 To date, one trial of PrEP has been completed in 
Ghana with women, but showed no significant differences in 
infections between those who used PrEP and those who used 
placebo. Two trials of tenofovir were stopped in Cambodia and 
Cameroon because of ethical controversies. 
Microbicides. Microbicides are female-initiated products 
applied to the vagina to prevent HIV infection. No microbicide 
products tested in efficacy trials (e.g. Carraguard, cellulose 
sulphate) have proven effective in reducing the risk of HIV 
infection.6 The results of the phase II HPTN 035 trial became 
available in early 2009, and demonstrated that while BufferGel 
did not reduce HIV risk among women, PRO 2000 gel reduced 
risk by 30%.16 However, these results were not statistically 
significant.16 The phase III trial of PRO 2000 results will be 
released later in 2009 and will provide additional evidence 
to conclusively determine whether PRO 2000 prevents HIV 
infection in women.16 The results of the phase IIB trial of 
tenofovir gel will be available in 2010. 
Behavioural interventions. A behavioural RCT, Project 
UNITY, is currently underway. It compares enhanced HIV risk-
reduction and vaccine education interventions with standard 
interventions used in HVTs.4 Results are expected in 2009.4 
Complexities of adding new tools to the package of 
prevention
The level of evidence needed for new methods seems to 
surpass what is accepted for current tools.6 When adding 
new tools to the prevention package, researchers will need to 
consider the strength of evidence generated from the efficacy 
trial and the degree to which results can be extrapolated to 
other populations and contexts.17 Specifically, researchers 
will need to assess the conclusiveness of the data, the need 
for further confirmatory trials, and the safety profile of the 
candidate product.18 There is no set standard for this task. 
For example, researchers in the HVTN 503/Phambili trial 
decided to offer circumcision to male participants as part of 
risk-reduction counselling and the standard of prevention 
based initially on results of the South African trial,  while 
WHO/UNAIDS cautioned that further research was needed to 
confirm the reproducibility and general applicability of these 
findings.12 However, the initial decision to provide circumcision 
to trial participants was strengthened by the results of two 
additional trials which became available before HVTN 503 
commenced. 
Also, several regulatory complexities may exist. Some 
new prevention technologies must be approved by national 
regulatory authorities to be used in a country (e.g. PrEP 
researchers will need to initiate a change of indication 
with the Medicines Control Council (MCC)); others (e.g. 
circumcision) will not. Furthermore, for some products 
licensure requirements may be unclear, e.g. there was some 
debate regarding how to proceed should acyclovir have shown 
to decrease HIV infection by suppressing herpes simplex virus 
type 2 (HSV-2). From one perspective acyclovir was already 
approved and licensed for the treatment of herpes; therefore if 
it was found effective in preventing HIV infection, it would not 
need to be approved/licensed again. However, from another 
perspective it was argued that acyclovir has an anti-HIV effect19 
that may have explained any decreases in HIV transmission, 
therefore requiring researchers to apply for a change of 
indication. Some regulatory authorities have not outlined their 
requirements for licensure of products such as microbicides 
or vaccines. However, regulators often require that to be 
licensed, new products must be tested in at least two RCTs 
or a single pivotal trial (phase III trial) that provides as much 
evidence of effectiveness as two trials would have.20 However, 
for interventions that are not medicines or devices, a national 
‘approval’ process is less defined, e.g. it is not clear whether 
government’s lack of objection to an intervention would 
constitute approval or whether active endorsement or policy 
development would be required. Furthermore, once regulatory 
obstacles are overcome, manufacturing, distribution and 
surveillance capacity may become important considerations.   
Furthermore, ethical guideline requirements that trials 
should not be conducted without consensus among all 
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research stakeholders on the standard of prevention2 may not 
adequately take into account how difficult consensus-building 
can be, that canvassing the opinion of affected parties may be 
morally relevant but not morally definitive,21 and that in some 
instances this procedural  requirement may serve to lower the 
substantive standard that such a package be ‘state of the art’. 
Lastly, when new tools are added to the standard of 
prevention, the incidence of HIV in large-scale late-phase trials 
is likely to decrease. When incidence is reduced, the statistical 
power of the study to detect significant differences decreases, 
making it increasingly difficult to demonstrate the efficacy of 
the candidate product.20 In fact, a high uptake of the prevention 
package was offered as a possible explanation of the reduced 
power of the MIRA diaphragm trial.15 Trials will therefore 
have to enrol more participants, and as trial size increases, so 
does the length and costs. For example, a study requiring 100 
HIV infections with a 30% effective prevention package will 
require 4 866 participants to have sufficient power to detect 
significant effects. This increases to 8 515 participants when 
the package becomes 60% effective.12 Such complications pose 
challenges for the development of more (and potentially more 
effective) prevention tools. When the addition of new tools will 
invalidate trial results or otherwise make trials impossible to 
run, then arguably the obligation to provide all such tools to 
participants is weakened. This is because invalid trial results 
mean that participants will have been exposed to risks for 
no purpose in that important societal knowledge for future 
beneficiaries will not be gained. In our view this is the ethical 
crux of the matter. Efforts12 to thoroughly explore this concern 
need to be strengthened. 
Recommendations for addressing complexities with 
adding new tools to the prevention package 
1.    There should be an expert consultation by HVT researchers, 
sponsors, regulatory authorities, community representatives 
and ethics committees to define the acceptable level of 
effectiveness to add new tools to the prevention package. 
Also, the threshold at which adding new tools will 
invalidate trial results should be explored.
2.    Efforts should be made to understand how decisions are 
(and will be) made to add new tools to the prevention 
package offered to HVT participants. 
3.    Developing country regulators should outline their 
requirements for the licensure of new products.8 
4.    Sponsors and international donors should consider how 
trial budgets will be expanded to take into account new 
prevention technologies.
Conclusions  
There has been little empirical exploration of what prevention 
services researchers currently provide to participants in HVTs, 
how they make decisions about what to provide, and their 
challenges and successes. Data are also limited on the degree 
to which service-delivery and decision-making practices 
correspond with standards in ethical guidelines. Empirical 
research is needed to fill this gap. Furthermore, new and 
promising results of products such as PRO 2000 gel plus the 
imminent possibility of positive results for PrEP or behavioural 
interventions indicate that HVT researchers must deliberate 
now about the implications for the prevention package offered 
to trial participants. 
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